Engflag

Min-Ovral

Quick links to important sections

Min-Ovral

Min-Ovral_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Min-Ovral

Property Description
Active ingredient Ethinylestradiol, Levonorgestrel
Form Oral Tablet
Pharmacological class Combined Oral Contraceptive (COC)
Common use Prevention of pregnancy (Contraception)
Origin Synthetic (Hormonal compounds)

Min-Ovral: Classification and Identity as a Combined Oral Contraceptive

Min-Ovral is a prescription-only medication that is scientifically categorized as a Combined Oral Contraceptive (COC). Its pharmacological classification places it within the therapeutic group of Hormonal Contraceptives for Systemic Use. This combination product is a reliable method of hormonal contraception, recognized for its efficacy in fertility management. The product's identity is defined by the precise, synthetic formulation of its two hormonal components, which allows it to systematically interfere with the reproductive cycle.

Composition and Form: Synthetic Hormonal Components

The medication is supplied as an oral tablet for systemic administration and is defined by its wholly synthetic composition. It contains two distinct active pharmaceutical ingredients (APIs): the synthetic estrogen Ethinylestradiol and the synthetic progestin Levonorgestrel. This pairing of Ethinylestradiol and Levonorgestrel is one of the widely used combinations in hormonal contraception. The simultaneous presence of both a synthetic estrogen and a synthetic progestin ensures the multi-layered biological intervention required for its consistent contraceptive efficacy.

General Purpose and Intended Use

The general purpose of Min-Ovral is to provide effective birth control for women of reproductive age seeking to manage their fertility. The anti-fertility effect is achieved by the hormones suppressing the body's natural reproductive processes, primarily by inhibiting ovulation. The formulation is used in a typical scenario where a woman desires a systemic, reversible, and highly effective method to prevent unintended pregnancy. The ingredients also contribute to reinforcing the biological barrier by altering cervical mucus and the uterine lining, serving as a comprehensive method of fertility management.

Regulatory References

  1. Ethinyl Estradiol and Levonorgestrel Oral Contraceptives
  2. Min-Ovral Product Information on Health Canada Register

What side effects are possible with Min-Ovral?

Possible Side Effects and Safety Information

The use of Min-Ovral (levonorgestrel/ethinyl estradiol) is associated with both common adverse reactions and serious safety risks, primarily related to vascular events.

Serious and Clinically Significant Risks

Thrombotic Events: The most critical risk is an increased incidence of arterial and venous thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (heart attack), and stroke. This risk is highest during the first year of use and is significantly compounded by certain factors, particularly cigarette smoking in women over 35 years of age (a major contraindication).

Other Serious Conditions: Regulatory information notes risks of liver tumors (benign or malignant), gallbladder disease, and hypertension (high blood pressure). The medication is contraindicated in women with uncontrolled hypertension, known thrombotic disorders, liver disease, or certain cancers.

Common Adverse Reactions

The most frequently reported adverse reactions include irregular uterine bleeding (spotting or breakthrough bleeding), nausea, headache, abdominal pain, and breast tenderness/pain. These common effects often decrease over the first few months of use. Other documented reactions include weight changes, mood changes, acne, and vaginitis.

Safety Monitoring and Restrictions

Monitoring: Careful clinical monitoring is required for women with pre-existing conditions such as well-controlled hypertension, diabetes, or depression, as these conditions may be affected or exacerbated. The medication must be discontinued if jaundice occurs, blood pressure rises significantly, or if depression recurs to a serious degree.

Surgical/Immobilization Risk: Use must be stopped at least four weeks before and through two weeks after major surgery or during prolonged immobilization due to the heightened risk of venous thromboembolism.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documentation for Min-Ovral (Ethinylestradiol/Levonorgestrel) defines the overdose profile as one with generally low acute toxicity, meaning acute overdosage is typically not associated with life-threatening outcomes.

Documented Overdose Manifestations

The official labeling confirms that the primary clinical manifestations following the ingestion of a large number of active tablets are often related to the hormonal components. These manifestations include:

  • Nausea and vomiting.
  • Vaginal withdrawal bleeding, which is a characteristic finding in females.
  • Other potential manifestations include breast tenderness and headache.

These same signs, particularly nausea and vomiting, are the anticipated effects should the active tablets be accidentally ingested by young children or prepubescent females.

Mandated Emergency Action

In the event of a known or suspected overdose, government regulatory guidance mandates that individuals seek immediate medical attention or contact a national Poison Control center for expert triage. Management for an overdose of this combined oral contraceptive is strictly symptomatic and supportive, as no specific antidote is known for this hormonal combination. Clinical monitoring may be required to observe the patient's vital signs and systemic stability.

Therapeutic Uses of Min-Ovral

What Min-Ovral Treats: Main Uses and Benefits

Min-Ovral provides a form of systemic support for fertility management and is commonly used for prevention of unintended pregnancy for women of reproductive potential. Furthermore, combined oral contraceptives are often used to help manage symptoms related to systemic imbalance in reproductive health. This use generally helps to support the attainment of a predictable monthly bleeding schedule, which contributes to improved cycle predictability and stability in fertility management.

The medication is relevant for easing the symptom burden across multiple domains, including severe cramping (primary dysmenorrhea), excessive menstrual blood loss (menorrhagia), and the symptomatic pelvic discomfort associated with endometriosis. It is also applied in managing manifestations of Polycystic Ovary Syndrome (PCOS) and may assist with managing hormonally-driven external symptoms, relevant for easing the symptom burden of acne. The medication is used when symptoms create noticeable physiological strain, helping to support general comfort during symptomatic phases.

Quick Fact: Supports Management of Severe Menstrual Distress

Supportive Management for Gynecological Symptoms

The medication is applied in addressing certain chronic, hormone-sensitive conditions. The medication may assist with managing hormonally-driven external symptoms, relevant for easing the symptom burden of acne.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Min-Ovral (Ethinylestradiol/Levonorgestrel) is authorized for use only in females of reproductive potential for conception control. Eligibility is governed by strict regulatory rules that define specific populations who must not use the medicine (contraindications).

The medicine is contraindicated for:

  • Women over age 35 who smoke.
  • Individuals with current or history of thrombotic disorders (e.g., deep vein thrombosis, pulmonary embolism, stroke, or coronary artery disease) or hereditary/acquired thrombophilias.
  • Patients with uncontrolled hypertension, active liver disease (including liver tumors), or known/suspected breast cancer or other estrogen-dependent neoplasia.
  • Any individual with known or suspected pregnancy.

Age and Status Limitations:

  • The medicine is not indicated for use before menarche or in postmenopausal women.
  • Use is not recommended for nursing mothers due to the potential effect on milk production.
  • A temporary restriction requires discontinuation at least four weeks before and through two weeks after major surgery or prolonged immobilization.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Min-Ovral (Ethinylestradiol/Levonorgestrel) is structured around high-risk combinations and substances that modify hormone exposure through liver metabolism. Co-administration of Min-Ovral is formally contraindicated with specific Hepatitis C combination drug regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the documented potential for significant ALT elevations.

Exposure-Modifying Substances

Category Documented Interacting Substances
Decreased Hormone Exposure Medicinal products classified as strong enzyme inducers, such as Rifampin, Phenytoin, and Carbamazepine. The herbal product St. John's wort is also documented to reduce hormone plasma concentrations.
Increased Hormone Exposure Certain drugs like Atorvastatin and Rosuvastatin are documented to increase the systemic exposure of the estrogen component.

Other Regulatory Constraints

Min-Ovral is formally contraindicated for co-administration with oral Tranexamic Acid due to the officially documented risk of thrombotic synergism. For administration convenience, a timing restriction is placed on the concomitant use of Colesevelam, which must be administered 4 or more hours apart from the contraceptive [Source 2.4]. Furthermore, the product is contraindicated in women with severe Hepatic Impairment as the hormones may be poorly metabolized.

Transient physiological states, such as severe vomiting or diarrhea, are noted in regulatory documents as potentially compromising hormone absorption and efficacy.

Mechanism of Action

Min-Ovral, a combination of levonorgestrel (progestin) and ethinyl estradiol (estrogen), exerts its primary pharmacological effects via the hypothalamic-pituitary-ovarian axis. The active components are transported systemically and interact with their respective intracellular steroid hormone receptors in target tissues, notably the pituitary gland and hypothalamus. Levonorgestrel functions as an agonist at the progesterone receptor, while ethinyl estradiol is an agonist at the estrogen receptor.

This agonism leads to a negative feedback loop, suppressing the pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus. Downstream, this suppression causes reduced synthesis and release of pituitary gonadotropins, specifically Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). The lowered gonadotropin levels inhibit follicular development and prevent the pre-ovulatory LH surge, thereby arresting the complex process of ovulation. Additionally, levonorgestrel induces changes in cervical tissue, increasing the viscosity and decreasing the permeability of cervical mucus, a physiological consequence that impedes the translocation of sperm into the upper reproductive tract.

Dosage and Administration Information

How to Use Min-Ovral

The administration of Min-Ovral (Ethinylestradiol/Levonorgestrel) is defined by a strict, repeating 28-day cyclic protocol. The medication is supplied as a monophasic fixed-dose oral tablet for systemic administration.

Official Administration Guidelines

The standardized use of this combined oral contraceptive (COC) is governed by specific procedural requirements and timing rules:

Scope Entity Official Administration Principle
Route of administration Oral administration only.
Dosing schedule One active tablet daily for 21 consecutive days, followed by 7 days of either inactive/placebo tablets or a tablet-free interval.
Frequency and Timing The tablet must be taken once daily at approximately the same time every day to maintain consistent systemic levels.
Contextual Instructions May be taken with or without food and must be ingested in the specific sequential order indicated on the blister pack.

Procedural Structure and Constraints

The administration protocol mandates that each subsequent pack must be started immediately following the 7-day tablet-free phase, regardless of whether a withdrawal bleed has stopped. There are two regimen initiation options: the Day 1 Start (beginning on the first day of menses) or the Sunday Start. When the Sunday Start is used, an additional non-hormonal back-up method is required for the first seven days of active tablet use, defining a procedural constraint for the initial cycle.

Furthermore, Min-Ovral is approved for women of reproductive potential, but the regimen is typically not initiated until at least four weeks after delivery in women who are not breastfeeding. Specific protocols exist for managing missed active tablets, a critical component of the administration rules necessary for maintaining contraceptive effectiveness.

Recent Clinical Evidence

Min-Ovral (a combination oral contraceptive containing ethinyl estradiol and norgestrel) is a prescription medication primarily indicated for the prevention of pregnancy. Its clinical evidence profile is well-established, with efficacy and safety findings supported by decades of research into combination hormonal contraception.

Effectiveness and Efficacy

Studies on combination oral contraceptives consistently demonstrate high effectiveness when used correctly and consistently. Clinical trials evaluate the Pearl Index, a measure of the number of pregnancies per 100 woman-years of use.

Study Type Reported Pearl Index (range) Context
Controlled Trials 0.1 to 0.9 Reflects perfect use under research conditions.
Typical Use 3 to 9 Reflects use in the general population, including occasional errors.

The effectiveness of Min-Ovral is derived from the actions of its two components: the estrogen component (ethinyl estradiol) suppresses ovulation, and the progestin component (norgestrel) thickens cervical mucus and alters the uterine lining.

Non-Contraceptive Benefits

Research has investigated additional therapeutic benefits associated with combination oral contraceptive use, though these effects are not the primary indication for Min-Ovral:

  • Menstrual Cycle Regulation: Users often experience more regular, shorter, and lighter menstrual bleeding, which may reduce the risk of iron-deficiency anemia.
  • Reduced Risk of Certain Cancers: Long-term use of combination oral contraceptives has been associated with a reduced lifetime risk of developing ovarian and endometrial cancers.

Safety and Tolerability

The safety profile of combination oral contraceptives has been extensively studied. The most significant risks are rare, including a small, increased risk of thromboembolic events (blood clots), myocardial infarction, and stroke, particularly in women who smoke or have certain underlying health conditions. Common, non-serious side effects often include nausea, breast tenderness, and breakthrough bleeding, which typically diminish after the first few cycles of use.

Frequently Asked Questions (FAQ)

Common questions about Min-Ovral (FAQ)

Q: Why is Min-Ovral considered a low-dose oral contraceptive?

Min-Ovral is generally regarded as a low-dose combined oral contraceptive because of its composition. Official labeling indicates the product contains 30 mu g of the estrogen component, ethinyl estradiol. The 30 mu g level of ethinyl estradiol is generally described in medical contexts as characteristic of low-dose formulations.

Q: How quickly does Min-Ovral start working after the first package?

The contraceptive protection from Min-Ovral is generally described in prescribing information as becoming effective after seven consecutive days of taking the active hormone tablets. For this reason, official administration guidelines describe the need for a non-hormonal back-up method during the first seven days if the regimen is not initiated on the first day of a person's menstrual period.

Q: Can taking antibiotics affect how Min-Ovral works?

Official drug interaction information notes that certain medications classified as enzyme inducers may reduce the hormone levels and potentially the effectiveness of the contraceptive. This includes the antibiotic Rifampin. A comprehensive list of documented interactions is available in the official labeling.

Q: Does Min-Ovral affect blood pressure?

Prescribing information notes that an increase in blood pressure (hypertension) has been associated with the use of oral contraceptives. The medicine is officially contraindicated in individuals with uncontrolled hypertension.

Q: Is Min-Ovral a combination pill or a progestin-only pill?

Min-Ovral is officially classified as a Combined Oral Contraceptive (COC). This means it contains two types of active hormone ingredients: the synthetic estrogen ethinyl estradiol and the synthetic progestin levonorgestrel.

Q: How long does it typically take for a person’s natural cycle to return after discontinuing Min-Ovral?

Regulatory guidance and patient information indicate that the body's ability to become pregnant and the typical menstrual cycle usually return relatively quickly after discontinuing a combination oral contraceptive like Min-Ovral. For most people, the natural cycle returns in the months following discontinuation.

Q: Is there a generic version of Min-Ovral available?

Yes, the active ingredients in Min-Ovral (levonorgestrel/ethinyl estradiol) are available in generic formulations. Regulatory bodies require these generic versions to demonstrate bioequivalence to the original reference product, meaning they deliver the same amount of medication to the body.

Q: Is Min-Ovral the same as other birth control pills that use levonorgestrel?

Min-Ovral contains a specific dosage combination of the progestin levonorgestrel and the estrogen ethinyl estradiol (30 mu g). While many contraceptives use levonorgestrel, other products may use different strengths or regimens that distinguish them from Min-Ovral.

Q: Is it true that Min-Ovral might help with acne?

The primary, officially indicated use for Min-Ovral is the prevention of pregnancy. Published research suggests that some combination oral contraceptives may be associated with managing acne in certain individuals.

Q: What is the difference between Min-Ovral and Min-Ovral 28?

The primary difference is the tablet count in the package: Min-Ovral 21 contains only 21 active hormone tablets. Min-Ovral 28 contains the same 21 active tablets plus 7 inactive (placebo) tablets that are included for continuous dosing convenience.

Q: How is Min-Ovral different from Min-Ovral and Lo/Ovral?

Both Min-Ovral and Lo/Ovral are brand names for combined oral contraceptives containing synthetic estrogen and progestin. The main difference lies in the specific hormone dosage of the active ingredients contained in each tablet. Both products contain different total amounts of hormones per cycle.

Q: Does grapefruit juice interact with Min-Ovral?

Official food interaction information indicates that consuming grapefruit or grapefruit juice may increase the body's exposure to the estrogen component, which is associated with a potential for increased side effects such as irregular bleeding.

Q: Is there any research on long-term use of Min-Ovral?

The safety and efficacy of combination oral contraceptives, including this formulation, are supported by decades of clinical experience and extensive research. Studies on long-term use have also indicated potential non-contraceptive benefits, such as an association with a reduced risk of certain cancers.

Q: Is Min-Ovral safe to use for women over 35?

The official contraindication is specific to women over 35 years of age who smoke due to a significantly increased risk of serious cardiovascular events. For non-smoking women over 35, eligibility is determined based on the absence of other contraindications.

Q: Is Min-Ovral known to affect fertility after a person stops taking it?

Regulatory guidance indicates that a person's ability to conceive (fertility) usually returns relatively quickly after stopping combination oral contraceptives. The effect of the hormones is generally reversible.

Q: Are there any eye-related issues described in the official product information for Min-Ovral?

Official safety information for Min-Ovral notes a rare risk of retinal vascular thrombosis (blood clots in the eye) and possible changes related to contact lens tolerance or vision changes are also noted in prescribing information.

Q: Can Min-Ovral cause mood changes?

Mood changes are listed among the commonly reported adverse reactions in the official prescribing information for Min-Ovral. As with many side effects, they may vary in severity over the first few months.

Q: What happens if a person stops taking Min-Ovral suddenly?

Discontinuing the medicine may lead to the return of the natural hormonal cycle, which can be associated with irregular periods or a change in the severity of pre-existing symptoms like menstrual pain.

Q: Does the manufacturer of Min-Ovral include any patient-specific instructions for use after childbirth?

Prescribing information advises against initiating the regimen until at least four weeks after delivery in women who are not breastfeeding. This is noted due to the increased risk of venous thromboembolism after childbirth.

Q: What is the general success rate described in studies for Min-Ovral?

The effectiveness of Min-Ovral is measured using the Pearl Index, which reports the number of pregnancies per 100 women-years of use. This index is lowest (indicating the highest success rate) under controlled clinical trial conditions and is higher when used under typical real-world conditions.

Q: Are there any known interactions between Min-Ovral and seizure medications?

Official interaction warnings include specific anticonvulsant medications such as phenytoin and carbamazepine. These drugs are classified as enzyme inducers that may reduce the hormone levels and potentially decrease the effectiveness of the contraceptive.

Q: Why is Min-Ovral often prescribed?

Min-Ovral is a combined oral contraceptive that is officially indicated and prescribed primarily for the prevention of pregnancy in women of reproductive potential. It is one of several widely studied hormonal contraceptive formulations available.

Q: What are the active ingredients in Min-Ovral-21?

The active ingredients in each hormone tablet of Min-Ovral-21 are the progestin levonorgestrel and the estrogen ethinyl estradiol. The tablets do not contain any other active pharmaceutical ingredients.

Q: Is Min-Ovral available over the counter in any regulated markets?

Min-Ovral is classified as a prescription-only medication in major regulated markets. This means it must be dispensed under the direction of a licensed healthcare provider.

Q: Do studies suggest any potential benefit of Min-Ovral for ovarian cysts?

While the primary indication is contraception, published clinical research on the combined oral contraceptive formulation suggests that its use can be associated with the resolution of functional ovarian cysts.

Q: What is the role of the inactive pills in the Min-Ovral 28-day pack?

The inactive (or placebo) tablets in the 28-day pack do not contain hormones and are intended to help a person maintain the habit of taking one tablet daily, ensuring the next pack of active hormone pills is started on the correct, scheduled day.

Q: Does Min-Ovral interact with any common anti-fungal medications?

Official prescribing information indicates that Min-Ovral may interact with medications, including those that influence how the body processes hormones in the liver. A comprehensive list of documented interactions is available in the official labeling.

Q: Are changes in breast tenderness a reported side effect of Min-Ovral?

Yes, breast tenderness or pain is listed in the official prescribing information as one of the commonly reported adverse reactions associated with the use of Min-Ovral. As with many common side effects, this symptom may decrease after the first few months.

Q: Can I take Min-Ovral if I have diabetes?

Regulatory guidance notes that the product may affect glucose tolerance. For women with pre-existing medical conditions, such as diabetes, careful monitoring is noted as necessary.

Q: Is Min-Ovral specifically approved for conditions other than contraception in any region?

While the official, primary indication is the prevention of pregnancy, combination oral contraceptives are also described in studies as being associated with non-contraceptive benefits, such as achieving more regular and lighter menstrual bleeding.

How should Min-Ovral be stored and disposed of?

How to Store and Dispose of Min-Ovral?

Min-Ovral (norgestrel and ethinyl estradiol tablets) must be stored under specific environmental constraints to maintain product stability, as documented in official regulatory labeling.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection The tablets must be protected from light. For opened packs (Min-Ovral 21 and 28), use the protective covering provided.
Safety Keep the medication out of the reach of children and pets.

Disposal Instructions

Disposal of unused or expired Min-Ovral should prioritize safety and regulation. The official recommendation is to utilize a drug take-back option if one is available in the area. If a take-back program is unavailable, follow the general FDA instructions for discarding non-flushable medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Min-Ovral found in:

A-Z Index: